April 29 (Reuters) - Danish drugmaker Novo Nordisk

has partnered with Hims & Hers Health's ( HIMS ) to

sell its popular weight loss drug through a bundled offering on

the telehealth company's platform, the two companies said on

Tuesday.

Customers will get access to the offerings of all dose

strengths of Wegovy and a membership at a price starting at $599

per month, Hims said.

The offering is available this week on the Hims & Hers

platform, it added.

The companies are building a longer-term roadmap of bundled

offerings that will have very unique value and pricing to

consumers that hopefully we're able to share in the coming

quarters, Hims CEO Andrew Dudum said.

Earlier this month, Hims said it plans to sell Eli Lilly's ( LLY )

Zepbound on its platform.

While Novo's Wegovy and Lilly's rival drug, Zepbound, were

in short supply, several telehealth companies were allowed to

sell cheaper copies of the treatments. The branded drugs have

since been removed from the U.S. Food and Drug Administration's

shortage list, potentially curtailing bulk compounding.

The company will continue to offer personalized compounded

versions of semaglutide on its platform, Dudum added.

Semaglutide is the active ingredient in Novo's Wegovy.